Aducanumab

国际站：Aducanumab

中文名：阿杜那单抗

CAS：1384260-65-4

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性： Aducanumab (BIIB037)，一种对聚集形式的淀粉样蛋白 (Aβ) 具有选择性的人单克隆抗体。 Aducanumab 具有脑穿透性，可用于阿尔茨海默病 (AD) 研究^[1]。

体内：Aducanumab (30 mg/kg，腹腔注射，单剂量) 在 22 个月大的 Tg2576 转基因小鼠中结合所有形态类型的脑 Aβ 斑块，包括弥漫性 Aβ 沉积和致密性 Aβ 斑块[1]。 Aducanumab (0.3-30 mg/kg, 腹腔注射, 每周一次, 6 个月) 在 9.5 到 15.5 个月大的 Tg2576 转基因小鼠中以剂量依赖性方式减少可溶性和不溶性 Aβ[1]。 Aducanumab (10 mg/kg, 腹腔注射, 每周, 6 个月) 可将 18 个月大的 Tg2576 小鼠的细胞内钙恢复至控制水平[2]。 Aducanumab (0.4-1 mg/mL, 脑室注射, 20 分钟) 在 Tg2576 小鼠中可导致淀粉样蛋白负荷快速减少，从而促进斑块清除[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 9.5- to 15.5-month-old Tg2576 transgenic mice [1] Dosage: 0.3-30 mg/kg Administration: Intraperitoneal injection (i.p.), weekly, 6 months Result: Increased recruitment of Iba-1-positive microglia to Aβ plaques. Animal Model: 18-month-old Tg2576 mice[2] Dosage: 10 mg/kg Administration: Intraperitoneal injection (i.p.), weekly, 6 months Result: Restored neurite baseline calcium to control levels. Decreased the number of neurites with elevated levels of calcium after 2 weeks. Decreased the percentage of cell bodies with calcium overload. Restored the levels of VILIP and SERCA to control levels. Increased the cell numbers of NR1 and NR2A. Animal Model: 22-month-old transgenic Tg2576 mice[2] Dosage: 0.4-1 mg/mL Administration: Intracerebroventricular injection (ICV), 20 min Result: Decreased the number of amyloid plaque. Decreased the size of the remaining individual plaques. Reduced amyloid plaque burden. Clinical Trial

参考文献：[1]. Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50-6.[2]. Kastanenka KV, et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. J Neurosci. 2016 Dec 14;36(50):12549-12558.